Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Nucleic Acid Therapeutics Market Value Growth And Long-Term Outlook
The nucleic acid therapeutics market has experienced significant growth in recent years. It is anticipated to expand from $6.94 billion in 2025 to $8.01 billion in 2026, with a compound annual growth rate (CAGR) of 15.4%. Historically, this growth can be attributed to factors such as the limited availability of nucleic acid therapeutics, a reliance on traditional small molecule therapies, the increasing demand for precision medicine, regulatory approvals for early gene therapies, and a rise in academic research focusing on gene modulation.
The nucleic acid therapeutics market is projected to expand significantly over the coming years, with its size forecast to reach $14.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.1%. This anticipated growth during the forecast period is driven by factors such as advancements in CRISPR and other gene-editing technologies, the broader application of lipid nanoparticle (LNP) delivery systems, the increasing acceptance of personalized nucleic acid therapies, growing partnerships between pharmaceutical and biotechnology companies, and increased investment in RNA-based therapeutics. Key trends emerging over the forecast period encompass the growing use of antisense oligonucleotides (ASOs) and siRNA treatments, the wider application of CRISPR-based and gene-editing therapeutics, an increase in targeted therapies for neuromuscular, metabolic, and oncological conditions, greater investment in both non-viral and viral delivery methods, and the rise of long non-coding RNA (lncRNA) and microRNA (miRNA) therapeutics.
Get A Free Sample Report With In-Depth Market Insights:
Nucleic Acid Therapeutics Market Expansion Drivers: What’s Shaping Future Growth?
The rising prevalence of genetic and chronic ailments is anticipated to fuel the expansion of the nucleic acid therapeutics market in the future. Genetic and chronic diseases describe conditions where inherited genetic elements influence the onset, advancement, or susceptibility to persistent health issues like diabetes, heart disease, cancer, and autoimmune conditions. This increase in genetics-related and chronic diseases can be largely attributed to enhancements in diagnostic tools, enabling more precise and earlier identification of these conditions. Nucleic acid therapeutics are valuable in addressing genetic and chronic diseases as they can precisely target and alter the fundamental genetic roots of these conditions through the regulation, repair, or silencing of particular genes, thereby providing exact and tailored treatment alternatives. For example, as reported by the Cystic Fibrosis Trust, a UK-based charity supporting individuals with cystic fibrosis, in October 2024, patient registrations for cystic fibrosis saw an increase from 11,148 in 2022 to 11,318 in 2023, marking a 1.5% year-over-year rise in patient numbers. Consequently, the growing incidence of genetic and chronic diseases is a key factor propelling the expansion of the nucleic acid therapeutics market.
Nucleic Acid Therapeutics Market Segment Analysis And Revenue Potential
The nucleic acid therapeutics market covered in this report is segmented –
1) By Therapy Type: Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), Gene Therapies, Aptamers, Other Therapy Types
2) By Therapeutic Area: Neuromuscular Disorder, Metabolic Disorders, Cardiovascular Disorders, Ophthalmological Disorders, Oncological Disorders, Other Therapeutic Areas
3) By Route Of Administration: Intravenous, Subcutaneous, Other Route Of Administrations
4) By Delivery Method: Viral Vector-Based Delivery Systems, Non-Viral Delivery Systems
5) By End-Use: Pharmaceutical Companies, Government And Academic Research Institutes, Biotech Companies
Subsegments:
1) By Antisense Oligonucleotides (ASOs): Phosphorothioate ASOs, 2’-O-Methyl ASOs, Locked Nucleic Acid (LNA) ASOs, Gapmer ASOs, Morpholino ASOs
2) By Small Interfering RNA (siRNA): Lipid Nanoparticle (LNP) Formulated siRNA, GalNAc-Conjugated siRNA, Chemically Modified siRNA, Naked siRNA
3) By Gene Therapies: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, CRISPR-Based Gene Therapy, Zinc Finger Nucleases (ZFNs), TALENs
4) By Aptamers: Ribonucleic Acid (RNA) Aptamers, Deoxyribonucleic Acid (DNA) Aptamers, Spiegelmers, Pegylated Aptamers
5) By Others Therapy Types: MicroRNA (miRNA) Therapeutics, Long Non-Coding RNA (lncRNA) Therapeutics, Ribonucleic Acid (RNA) Editing Therapies, Ribozymes
Nucleic Acid Therapeutics Market Strategic Trends: What Defines The Next Growth Phase?
Leading firms within the nucleic acid therapeutics market are concentrating on creating novel therapies, like antisense oligonucleotide therapy, to target and deactivate particular disease-inducing genes, thereby providing precise therapeutic solutions for genetic conditions and rare illnesses. This particular therapy employs brief, manufactured strands of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to either inhibit or alter the manifestation of specific genes implicated in disease processes. As an illustration, during December 2024, Ionis Pharmaceuticals Inc., a biotechnology company based in the US, secured U.S. Food and Drug Administration (FDA) approval for TRYNGOLZ (olezarsen). This approval was for its use as an additional therapy to diet for reducing triglyceride levels in adults with a diagnosis of familial chylomicronemia syndrome (FCS), which is a rare genetic condition marked by severe hypertriglyceridemia (sHTG) and an elevated risk of acute pancreatitis (AP). This treatment stands as the inaugural FDA-approved option providing substantial and lasting triglyceride reduction for this group of patients, coupled with a clinically significant reduction in AP incidence when paired with a low-fat diet. It is engineered for convenient self-application through a once-monthly auto-injector.
Nucleic Acid Therapeutics Market Key Players Shaping Industry Direction
Major companies operating in the nucleic acid therapeutics market are Pfizer Inc., Novartis AG, Moderna Inc., BioNTech SE, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., CureVac SE, Sangamo Therapeutics Inc., Beam Therapeutics Inc., Arbutus Biopharma Corporation, Silence Therapeutics plc, Copernicus Therapeutics Inc.
View The Full Nucleic Acid Therapeutics Market Report:
Nucleic Acid Therapeutics Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the nucleic acid therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucleic acid therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
